News

Seattle Genetics has completed enrollment in its pivotal clinical trial of brentuximab vedotin (SGN-35), for relapsed and refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted

Santhera and Biovail have signed a license agreement for Santhera’s JP-1730/fipamezole. Biovail has acquired the US and Canadian rights to develop and commercialise the drug for the treatment

Foamix has received US Patent No. 7575739 pertaining to its foam technology. The patent covers foam compositions, suitable for the treatment of heat and chemical burns, wounds, bacterial,

Resolvyx has reported positive data from a phase 2 clinical study evaluating RX-10045, a resolvin administered as a topical eye drop for the treatment of patients with chronic

Celentyx has entered into a drug reprofiling agreement with Meiji Seika Kaisha to seek alternative development paths for Meiji drug candidates, using an application of the Immuno-Profiling platform

Tikcro has reported that the US Department of Health and Human Services (HHS) has granted orphan drug status to BioCancell’s BC-819 drug. It is currently in phase I/IIa

Abbott has received approval from Health Canada for the Xience V Everolimus Eluting Coronary Stent System, for the treatment of coronary artery disease (CAD). Reportedly, Xience V is

CytRx has reported positive results of the study evaluating arimoclomol. The data demonstrated that arimoclomol exhibited both significant neuroprotective and neuroregenerative effects in brain cells of animals induced

Covidien has launched Leak Compensation software option for the Puritan Bennett 840 ventilator. The company claims that the new feature will provide a ventilation solution in high-leak environments,